Welcome to our dedicated page for Modular Med SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Modular Medical, Inc. (Nasdaq: MODD) files a range of reports and disclosures with the U.S. Securities and Exchange Commission (SEC) that document its activities as a development-stage medical device company focused on insulin delivery technology. This page aggregates those SEC filings and pairs them with AI-powered summaries to help readers understand the key points in each document.
For Modular Medical, current reports on Form 8-K are especially relevant. The company has used 8-K filings to describe material definitive agreements for underwritten public offerings of common stock and accompanying warrants, warrant inducement arrangements, and related gross proceeds. These filings also outline terms such as exercise prices, warrant durations, over-allotment options, and underwriter compensation. Other 8-Ks disclose Nasdaq notices regarding the company’s compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, including the time periods granted to regain compliance.
Registration statements on Form S-3 and other referenced registration statements are important for understanding how Modular Medical registers shares underlying warrants and other securities issued in its financings. Filings also confirm the company’s incorporation in Nevada and its status as a development-stage medical device company, as well as providing context for its capital structure.
On this page, AI-generated overviews highlight the main elements of each filing, such as new financing transactions, warrant terms, listing compliance developments, and references to the company’s insulin delivery technology focus. Users can quickly identify which documents address topics like public offerings, private placements, or Nasdaq communications, while still having access to the full text of the official SEC filings for detailed review.
Modular Medical, Inc. director Philip Sheibley reported buying company securities in an underwritten public offering. On December 11, 2025 he acquired 22,000 shares of common stock, bringing his direct holdings to 97,513 shares. He also acquired warrants with a $0.45 exercise price covering 11,000 shares of common stock, which are immediately exercisable and expire on December 11, 2030, resulting in 11,000 derivative securities held. The filing further notes that on the same date he purchased 60,000 shares of common stock and warrants to buy 30,000 shares at an offering price of $0.77 for each two shares of common stock and one warrant.
Modular Medical, Inc. entered into an underwriting agreement for a firm commitment public offering of 12,173,000 shares of common stock, together with accompanying warrants exercisable for up to 6,086,500 shares. The transaction is expected to generate approximately
Each two shares of common stock are sold with one warrant at a combined price of
Modular Medical, Inc. director and >10% owner Morgan C. Frank received stock option awards on
Jeff D. Goldberg, a Director of Modular Medical, Inc. (MODD), reported a securities transaction on Form 4 showing the grant of a stock option on 09/30/2025. The option has an exercise price of $0.70, covers 7,500 shares of common stock, and is exercisable immediately with an expiration date of 09/30/2035. The filing states the option was granted under the company’s Outside Director Compensation Plan and was fully vested and exercisable on the grant date. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Goldberg on 10/02/2025. Column 9 reports total beneficial ownership of the derivative class as 7,500 options.
Philip Brent Sheibley, a director of Modular Medical, Inc. (MODD), was granted an option to purchase 7,500 shares of common stock on 09/30/2025. The option has an exercise price of $0.70, was fully vested and exercisable on the grant date, and expires on 09/30/2035. The grant was made under the issuer's Outside Director Compensation Plan. The reported position after the transaction is 7,500 options held directly. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Steven G. Felsher, a director of Modular Medical, Inc. (MODD), reported insider transactions dated 09/30/2025. He acquired 750 shares of common stock and was granted an option to purchase 7,500 shares at an exercise price of $0.70. The option was fully vested and exercisable on the grant date and has an expiration date of 09/30/2035. Following the reported non-derivative transaction, the reporting person beneficially owns 193,177 shares. Both the shares and the option were issued under the issuer's Outside Director Compensation Plan. The Form 4 was signed on behalf of Mr. Felsher by an attorney-in-fact on 10/02/2025.
Modular Medical, Inc. entered into inducement agreements with certain holders of existing warrants, prompting them to exercise a portion of their warrants at a reduced cash exercise price of
In return, Modular Medical will issue new warrants to purchase approximately 2,747,314 shares of common stock, with an exercise price of
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh reported collective beneficial ownership of Modular Medical, Inc. common stock equal to 2,068,958 shares, representing 3.81% of the outstanding class based on 54,247,388 shares. The filing shows no sole voting or dispositive power; all voting and dispositive power is shared. An exhibit clarifies the holders directly own 1,548,125 shares and hold warrants to purchase 520,833 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control. Signatures for the filers are included.